Open-house drug rebate agreements for infliximab, excluding the 120 mg strength, ATC L04AB02

Summary

This is an open-house model for non-exclusive drug rebate agreements concerning infliximab, excluding the 120 mg strength (ATC L04AB02). The contracting authority intends to conclude identical, non-negotiable agreements with every interested pharmaceutical company that meets the requirements; this is not a competitive procedure involving a selection decision. The earliest contract start date is 1 November 2026, and all agreements end on 31 October 2028. Agreements may be concluded during the term, but no later than 3 September 2028, and may be terminated with one month's notice to the end of a month. Eligible companies must submit the completed and signed agreement, the annex specifying the covered medicines, and a signed reliability declaration. Documents may be submitted on paper with handwritten signatures or electronically with a qualified electronic signature. Complete and correct documents received by the 3rd day of a month generally allow the agreement to start on the first day of the following month; otherwise, the start is postponed to the first day of the following month after that. The official tender documents must be checked for the detailed instructions and conditions.